GOTHENBURG, Sweden,
Sept. 17, 2021 /PRNewswire/ --
Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease
pharmaceutical company developing innovative medicines for severe
lung disorders today announces the dosing of the first patients in
the company's global phase 3 trial of C21 in COVID-19
(ATTRACT-3).
- Previously reported positive phase 2 trial results strongly
support further evaluation of the Vicore AT2 receptor agonist C21
in
COVID-19
- The pivotal phase 3 trial is currently approved in the US,
Ukraine, South Africa, Brazil, Czechia, Philippines and India to investigate the efficacy and safety
of C21 in hospitalized patients with COVID-19
ATTRACT-3 is the pivotal trial in which C21, an angiotensin II
type 2 receptor (AT2R) agonist, is tested for the treatment of
COVID-19 with the objective of generating key efficacy and safety
data for assessment by regulatory bodies, including the US FDA. The
first doses have now been administered and currently 9
sites are initiated in the US, Ukraine, Brazil, and South
Africa.
"There remains a need for an efficient treatment of patients
with COVID-19. To date, only 31% of the global population has been
fully vaccinated and the rapid emergence of virus variants
threatens to complicate control of the disease. Based on positive
results from the phase 2 trial, we look forward to investigate the
efficacy and safety of C21 in COVID-19," said Dr. Maureen Horton, M.D., Professor of Medicine at
Johns Hopkins University School of
Medicine and the coordinating investigator of ATTRACT-3.
ATTRACT-3 is a randomized, double-blind, placebo-controlled,
multinational, phase 3 trial which will include 600 adult patients
hospitalized with COVID-19 requiring oxygen support but not
mechanical ventilation. The primary objective is to evaluate the
effect of C21 on recovery from COVID-19. Vicore's phase 2 trial in
COVID-19 (ATTRACT) showed that C21 significantly reduced the
extended need for supplemental oxygen therapy, indicating faster
recovery for patients treated with C21 compared to placebo.
In ATTRACT-3, patients will be randomized to receive 100 mg C21
or placebo twice daily on top of standard of care for 14 days and
be followed for 60 days. Trial start-up activities are ongoing at
more than 40 clinical sites globally. Topline results from
ATTRACT-3 are expected during the first half of 2022.
"The current SARS coronavirus could be just a few mutations
away from evading existing COVID-19 vaccines and there is still a
huge unmet need for a therapy that could restore lung function in
patients with moderate to severe disease," said Carl-Johan Dalsgaard, CEO of Vicore.
"ATTRACT-3 is a global trial. Our judicious choices of geographical
focus allow us to expect a steady patient recruitment, capture a
broad spectrum of virus variants and to be able to report the
results on schedule during the first half of 2022."
C21 in COVID-19 – improved respiratory outcomes
Results from the phase 2 ATTRACT trial demonstrated the ability
of C21 to significantly reduce the need for supplemental oxygen in
hospitalized patients with COVID-19 (90% reduction of risk in
C21-treated patients compared to those on placebo at day 14;
p=0.003), with numerically fewer deaths and cases of patients
requiring mechanical ventilation in the C21-treated group.
C21 - a first-in-class AT2R agonist
C21 is a first-in-class, orally available, low molecular weight,
angiotensin II type 2 receptor (AT2R) agonist that activates the
"protective arm" of the renin-angiotensin system (RAS). The
compound has shown robust effects in human idiopathic pulmonary
fibrosis (IPF) lung slices and a phase 2 proof-of-concept trial in
IPF is currently ongoing. Given the therapeutic potential of AT2R
agonism in several additional indications with significant unmet
medical needs, Vicore has intensified the efforts to develop
proprietary follow-up molecules with differentiated profiles.
For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
E-mail: carl-johan.dalsgaard@vicorepharma.com
This information was submitted for publication on
September 17, 2021 at 08.00
CET.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/vicore-pharma-holding-ab/r/vicore-starts-dosing-of-first-covid-19-patients-in-the-global-phase-3-trial-attract-3,c3416829
The following files are available for download:
https://mb.cision.com/Main/15668/3416829/1469452.pdf
|
Vicore starts dosing
of first COVID-19 patients in the global phase 3 trial
ATTRACT-3
|